GMP-conform production of [68Ga]Ga-NeoB for positron emission tomography imaging of patients with gastrointestinal stromal tumor

Marc Pretze (marc.pretze@ukdd.de)
University Hospital Carl Gustav Carus, TU Dresden
https://orcid.org/0000-0002-6432-5694

Laura Reffert
University Hospital Mannheim of University of Heidelberg Faculty of Medicine Mannheim: Universitätsklinikum Mannheim

Steffen Diehl
University Hospital Mannheim of University of Heidelberg Faculty of Medicine Mannheim: Universitätsklinikum Mannheim

Stefan O. Schönberg
University Hospital Mannheim of University of Heidelberg Faculty of Medicine Mannheim: Universitätsklinikum Mannheim

Carmen Wängler
University Hospital Mannheim of University of Heidelberg Faculty of Medicine Mannheim: Universitätsklinikum Mannheim

Peter Hohenberger
University Hospital Mannheim of University of Heidelberg Faculty of Medicine Mannheim: Universitätsklinikum Mannheim

Björn Wängler
University Hospital Mannheim of University of Heidelberg Faculty of Medicine Mannheim: Universitätsklinikum Mannheim

Research article

Keywords: [68Ga]Ga-NeoB, GRPR, GMP, PET/CT, metastatic GIST

DOI: https://doi.org/10.21203/rs.3.rs-446161/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

**Background:** $[^{68}\text{Ga}]{\text{Ga}}$-NeoB is a novel DOTA-coupled Gastrin Releasing Peptide Receptor (GRPR) antagonist with high affinity for GRPR and good in vivo stability. This study aimed at (1) the translation of preclinical results to the clinics and establish the preparation of $[^{68}\text{Ga}]{\text{Ga}}$-NeoB using a GMP conform kit approach and a licensed $^{68}\text{Ge}/^{68}\text{Ga}$ generator and (2) to explore the application of $[^{68}\text{Ga}]{\text{Ga}}$-NeoB in patients with gastrointestinal stromal tumors (GIST) before and/or after interventional treatment (selective internal radiotherapy, irreversible electroporation, microwave ablation).

**Results:** Validation of the production and quality control of $[^{68}\text{Ga}]{\text{Ga}}$-NeoB for patient use had to be performed before starting the GMP production. Six independent batches of $[^{68}\text{Ga}]{\text{Ga}}$-NeoB were produced, all met the quality and sterility criteria and yielded $712 \pm 73$ MBq of the radiotracer in a radiochemical yield of >50%, a radiochemical purity of >95% and a molar activity of $14.2 \pm 1.5$ GBq/µmol within 20 min synthesis time and additional 20 min quality control. Three patients (2 females, 1 male, 51–77 yrs of age) with progressive gastrointestinal stromal tumor metastases in the liver or peritoneum not responsive to standard tyrosine kinase inhibitor therapy underwent both $[^{68}\text{Ga}]{\text{Ga}}$-NeoB scans prior and after interventional therapy. Radiosynthesis of $^{68}\text{Ga}$-NeoB was performed using a kit approach under GMP conditions. No specific patient preparation such as fasting or hydration was required for $[^{68}\text{Ga}]{\text{Ga}}$-NeoB PET/CT imaging. Contrast-enhanced PET/CT studies were performed. A delayed, second abdominal image was acquired at 120 minutes p.i. of administration of the first dose of $[^{68}\text{Ga}]{\text{Ga}}$-NeoB.

**Conclusions:** A fully GMP compliant kit preparation of $[^{68}\text{Ga}]{\text{Ga}}$-NeoB enabling the routine production of the tracer under GMP conditions was established for clinical routine PET/CT imaging of patients with metastatic GIST and proved to adequately visualize tumor deposits in the abdomen expressing GRPR. Patients could benefit from additional information derived by $[^{68}\text{Ga}]{\text{Ga}}$-NeoB diagnosis to assess the presence of GRPR in the tumor tissue and monitor antitumor treatment.

Introduction

Gastrointestinal stromal tumors (GIST) are rare soft tissue mesenchymal tumors occurring in the gastrointestinal tract and are thought to be derived from the cells of Cajal, which drive peristalsis in the intestine [1, 2]. In GIST with high risk of developing metastases, early detection of metastases detection of GIST with high sensitivity and by non-invasive methods would be an important improvement to allow for immediate treatment and to monitor or predict of the efficacy of therapy which currently is mainly influenced by assessing the type of mutations in $\text{KIT}$ or $\text{PDGFRA}$ gene [3].

In this regard, morphological and functional imaging methods may be important for detection, staging and to follow-up of GIST patients undergoing therapy. Computed tomography (CT) is the most frequently used morphological imaging procedure, although it lacks sensitivity and/or specificity. Functional imaging with positron emission tomography (PET) using 2-deoxy-2-$[^{18}\text{F}]$fluoro-d-glucose combined with
computed tomography (18F)FDG PET/CT) is the most commonly used nuclear medicine functional imaging modality in clinic routine and has shown to be advantageous over morphological imaging procedures alone when assessing therapy response. However, earlier studies using 18F)FDG PET/CT for GIST detection reported only the low/moderate sensitivity [4]. Hence, more accurate, specific and sensitive non-invasive diagnostic tools visualizing GIST are needed.

The gastrin-releasing peptide receptor (GRPR), also called bombesin receptor 2 (BB2) [5], is a target for noninvasive PET imaging of various types of cancer [6, 7]. Since overexpression of the GRPR has been reported in various cancer types, e.g. prostate cancer [8], breast cancer [9], gastrointestinal stromal tumors (GISTs) [10] and other tumors [11]. Targeting the GRP receptor with radioligands has a significant impact on the specific and sensitive detection and treatment of GRPR-expressing tumors [12]. Bombesin (BBN) is a peptide with high affinity to the GRPR [13, 14]. Therefore, various radiolabeled bombesin-based peptide ligands have been extensively used to target GRPR-expressing tumors such as GISTs [10, 15, 16]. Derived from BBN, the truncated BBN7-14 sequence was developed, showing nearly the same affinity to GRPRs but with higher stability than bombesin. Hence, BBN7-14 has been used for the development of various radiopharmaceuticals with positron emitters such as 18F [17], 64Cu [18] and 68Ga [19] for PET, with gamma emitters such as 99mTc [20] for single photon emission computed tomography (SPECT), and with radionuclides such as 90Y [21], 111In [22] and 177Lu [23] for endoradiotherapy. Additionally, optimization of the stability and affinity of the bombesin analogs has been explored by changing l- to d-amino acids [24], utilizing triazole backbones in the peptide [25] and applying multimerization [26, 27].

Recently, [68Ga]Ga-NeoB (formerly known as NeoBOMB1) was developed, a novel 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetra acetate (DOTA)-coupled bombesin-based GRPR antagonist, which showed a high affinity for GRPR (IC50 = 1.17 ± 0.06 nM [28]) and high tumor uptake in preclinical studies in a xenograft mouse model (30.7 ± 3.9 %ID/g 4h post injection (p.i.) in PC3 tumor-bearing mice) accompanied by an good in vivo stability (5 min p.i. >95% intact, 30 min p.i. >90% intact) [28]. [68Ga]Ga-NeoB might have significant impact on the detection and treatment of GRPR expressing tumors such as like GIST [29]. Labelled with therapeutic radionuclides the peptide NeoB could also be useful for the treatment of imatinib-resistant GIST [7].

The purpose of our study was to explore the applicability of [68Ga]Ga-NeoB for the determination of the status of GIST in patients with different GRPR expression levels confirmed by previous biopsies of those lesions. Furthermore, the GMP compliant production of [68Ga]Ga-NeoB was established in our good manufacturing practice (GMP) environment including risk management, installation qualification (IQ), operation qualification (OQ) and validation of the process in six independent productions of [68Ga]Ga-NeoB following most recent guidelines [30].

In addition, the applicability of [68Ga]Ga-NeoB for visualization of GIST metastases before and/or after selective and patient-oriented specific interventional therapy (selective internal radiotherapy (SIRT), irreversible electroporation (IRE), microwave ablation (MWA)) was assessed.
Methods

Radiochemistry

The $^{68}$Ge/$^{68}$Ga-generator used holds a license for patient application according to the European pharmacopeia and was purchased from Eckert&Ziegler (1.85 GBq, GalliaPharm, Eckert & Ziegler, Berlin, Germany). The NeoB radiolabeling kit was received from Advanced Accelerator Applications S.A. (AAA). The kit consisted of a vial containing the lyophilized NeoB precursor and additives and a second vial containing the reaction buffer. For automated generator elution, we used an automated synthesis module (Scintomics GRP, Fürstenfeldbruck, Germany) together with a cartridge kit for $^{68}$Ga-radiolabeling using this module (SC-103, ABX, Radeberg, Germany). Analytical (radio-)HPLC was performed on a Shimadzu HPLC system (Nakagyo-ku, Kyōto, Japan), equipped with a reverse phase column (Merck LiChrospher 100 RP-18; 125x3 mm), a UV-diode array detector (254 nm) and a scintillation radiodetector (Pomo, Elysia-Raytest, Straubenhardt, Germany). The solvent system used was a gradient of acetonitrile:water (containing 0.1% TFA) (0–20 min: 10–90% acetonitrile). $[^{18}\text{F}]$FDG was commercially obtained (Life Radiopharma f-con GmbH, Germany).

$^{68}$Ga-Radiolabeling

The whole radiotracer production was performed inside a hot cell isolator (cleanroom class A, ITD, Dresden-Rossendorf, Germany) under GMP conditions 4 mL 0.1 M suprapur HCl were automatically eluted through the $^{68}$Ge/$^{68}$Ga-generator and through a sterile filter (Millex-GS 0.22 µm, SLGSV255F, Millipore) directly into the reaction vial containing the NeoB precursor (50 ± 5 µg, 31.7 ± 0.6 nmol), resulting in a total reaction mixture volume of 3 mL containing 1100 ± 100 MBq $^{68}$Ga. Subsequently, the kit labeling buffer (0.57 ± 0.3 mL 1 M formic acid, pH 5) and the antioxidant (gentisic acid) was added. Silicon-coated cannulas (0.6 × 60 mm, Sterican, B. Braun) were used throughout the whole synthesis process. Radiolabeling was performed at pH 3.6–4.0 for 7–10 minutes at 89°C inside the reaction vial in a heating block (95°C). The resulting solution contained 712 ± 73 MBq $[^{68}\text{Ga}]$Ga-NeoB in a radiochemical purity (RCP) of 96–99%, as confirmed by radio-thin-layer chromatography (radio-TLC) and radio-HPLC ($t_R$ = 9.7 min).

Quality control under GMP conditions for the patient use

The quality control (QC) of the injectable radiotracer solution was performed on an Elysia-Raytest QC-Cubicle compact unit within a cleanroom class D environment. The in-house production of radiopharmaceuticals is regulated in the German Pharmaceuticals Act and the European Pharmacopeia. There are monographs for example for $[^{68}\text{Ga}]$Ga-Octreotide [31] on which the quality control (QC) was based on. The following criteria were tested: the pH value has to be between 3.0–4.0. A bubble-point test of the sterile filter was performed. The radiochemical purity as determined by radio-TLC and radio-HPLC have to exceed > 97% and > 95%, respectively. The half-life of the product has to be 1.133 ± 0.1 h and was determined using an activimeter (Elysia Raytest). The nuclide purity has to exceed 99.999% and was
determined by gamma spectroscopy at an energy of the γ-line to be $511 \pm 70$ keV. The product was also tested for endotoxins using an Endosafe unit (Charles River, Wilmington, MA, USA), and the endotoxin level had to be below 35 EU/mL in a maximum application volume of 5 mL. Finally, the product was externally tested for sterility.

**Validation of production under GMP conditions**

The validation of the production process was performed on six independent $^{68}$Ga-Ga-NeoB syntheses which met the above mentioned criteria.

The generator was eluted automatically using the mentioned GRP module equipped with an 20 mL syringe by pushing 3 mL of 0.1 M HCl through the generator (2 mL/min) and a sterile filter into the reaction vial containing the precursor for $^{68}$Ga-Ga-NeoB [32].

**$^{68}$Ga-NeoB PET/CT Imaging Protocol**

A low-dose-CT (Siemens Biograph mCT, Biograph 40 VA44A, 32 + 8-line-CT, PETsyngo software VG51C) and then early whole-body PET/CT images were acquired from vertex to mid thighs with 8 bed positions and 3-min emission scans per bed position at 60 min after intravenous administration of the $^{68}$Ga-Ga-NeoB of 1.5–2 MBq/kg (135–229 MBq) into the antecubital vein. Contrast-enhanced PET/CT studies were performed on a 40-slice PET/CT scanner with 80 ml arterial contrast (Imeron). A delayed, second abdominal PET image was acquired at 120 minutes p.i. of the $^{68}$Ga-Ga-NeoB. Two experienced nuclear medicine physicians manually drew regions of interest on the liver lesions for each image using 3-dimensional ellipsoid isocontouring with the assistance of the corresponding CT images. The results were expressed as SUV$_{mean}$ and SUV$_{max}$.

**Results**

**Validation runs for $^{68}$Ga-Ga-NeoB**

The results of the validation runs are summarized in Table 1. Runs with a different buffer amount were performed to evaluate and validate the possible effect of inaccuracies during the addition by different operators. The elution of the generator was performed with 5.5 mL 0.1 M HCl (EZAG), resulting in 5.0 mL $^{68}$Ga-solution in the reaction vial and not less than 0.5 mL buffer solution (maximum 0.55 mL). In comparison to productions A (0.50 mL buffer solution) the insignificant higher amount (0.55 mL buffer solution) in productions B resulted in the same RCP using the TLC-method, but the RCP determined by HPLC demonstrated a slightly higher RCP. The production-SOP for $^{68}$Ga-Ga-NeoB has to instruct to use at minimum an amount of buffer of 0.50 mL. In conclusion, all six consecutive runs were inside of all the specifications yielding $712 \pm 73$ MBq of $^{68}$Ga-Ga-NeoB in a radiochemical yield of > 95%. The room conditions were proper and the devices are qualified for the production; thus the production process as carried out was demonstrated to be valid for patient production of $^{68}$Ga-Ga-NeoB.
Table 1
Results of the validation runs of $[^{68}\text{Ga}]$Ga-NeoB.

| Run # | batch #       | Reaction | Quality control | Buffer | temp. | yield** | pH  | radionuclide purity | RCP: HPLC / TLC | Sterile |
|-------|---------------|----------|----------------|--------|-------|---------|-----|---------------------|------------------|---------|
|       |               |          |                | Buffer |       |         |     |                     |                  |         |
|       |               |          |                |        |       |         |     |                     |                  |         |
|       |               |          |                | buffer |       |         |     |                     |                  |         |
|       |               |          |                | HCl*   |       |         |     |                     |                  |         |
|       |               |          |                | [ml]   |       |         |     |                     |                  |         |
|       |               |          |                | temp.  |       |         |     |                     |                  |         |
| A-1   | CT00516004    | 0.50     | 5.0            | HCl*   | 95.1°C | 765.2   | 3.5 | >99.999%            | yes             | 96.1%   |
|       | F03517002     |          | 10 min         | buffer |       |         |     | 99.0%               |                  |         |
| A-2   | CT00516004    | 0.50     | 5.0            | HCl*   | 94.9°C | 716.0   | 3.5 | >99.999%            | yes             | 96.4%   |
|       | F03517002     |          | 9 min          | buffer |       |         |     | 98.7%               |                  |         |
| A-3   | CT00516004    | 0.50     | 5.0            | HCl*   | 95.1°C | 568.0   | 3.4 | >99.999%            | yes             | 97.0%   |
|       | F03517002     |          | 8 min          | buffer |       |         |     | 99.3%               |                  |         |
| B-1   | CT00516004    | 0.55     | 5.0            | HCl*   | 95.0°C | 745.6   | 3.8 | >99.999%            | yes             | 98.5%   |
|       | F03517002     |          | 8 min          | buffer |       |         |     | 99.2%               |                  |         |
| B-2   | CT00516004    | 0.55     | 5.0            | HCl*   | 95.0°C | 756.2   | 3.8 | >99.999%            | yes             | 97.0%   |
|       | F03517002     |          | 10 min         | buffer |       |         |     | 98.5%               |                  |         |
| B-3   | CT00516004    | 0.55     | 5.0            | HCl*   | 95.2°C | 722.0   | 3.7 | >99.999%            | yes             | 98.7%   |
|       | F03517002     |          | 7 min          | buffer |       |         |     | 99.4%               |                  |         |

*: Elution volume minus 0.5 mL dead volume of the tubing

**: measured 2–5 minutes after cool down

**: second generator elution of the day (first elution 2.5 h before)

$[^{68}\text{Ga}]$Ga-NeoB: Clinical PET/CT investigations

For an implementation in clinical routine, three patients (21, 10, 51–77 a) with biopsy proven, metastatic GIST were examined with the GMP-produced $[^{68}\text{Ga}]$Ga-NeoB via PET/CT for staging purposes after they had been treated by antiproliferative drug therapy (imatinib, sunitinib, regorafenib) followed by SIRT, IRE or MWA. Image acquisition, attenuation correction, fusion, reconstruction and post-processing was performed on a dedicated workstation. SUV$_{\text{max}}$ was determined both on the initial whole-body and on the later focused imaging.
Patient #1 (male, 57 years old, small bowel GIST with peritoneal and progressive liver metastases after 3rd line therapy carrying an exon 11 and a secondary exon 17 mutation) received $^{18}$F-FDG PET/CT for staging and two of the progressive liver metastases in segment VII and segment II/III were depicted. The patient underwent subsequent SIRT therapy. Four months after therapy the patient received $^{68}$Ga-Ga-NeoB (229 MBq) for follow-up staging (Fig. 2) with low accumulation in the lesion in liver segment VII ($S_{\text{UV}_{\text{max}}} \text{ early of 1.4, } S_{\text{UV}_{\text{max}}} \text{ late of 3.3}$), but with persistence of the radiotracer in liver segment II/III ($S_{\text{UV}_{\text{max}}} \text{ early of 6.3, } S_{\text{UV}_{\text{max}}} \text{ late of 16.1}$), indicating still vital tumor tissue. Thus, the patient again underwent IRE on the left lobe (segment II/III). In comparison to the preliminary examination with $^{18}$F-FDG, two newly occurring demarcated peritoneal metastases in the right hemiabdomen with increased nuclide uptake ($S_{\text{UV}_{\text{max}}} \text{ early of 3.3 and 5.7, } S_{\text{UV}_{\text{max}}} \text{ late 6.4 and 17.9, respectively}$) were detected with $^{68}$Ga-Ga-NeoB. In addition, physiological distribution of $^{68}$Ga-Ga-NeoB was found in the study area. At a three-month $^{18}$F-FDG PET/CT follow-up the patient showed further progressive disease.

Patient #2 (female, 77 years old, small bowel GIST with progressive peritoneal and soft tissue metastases under third line therapy carrying an exon 11 and two different secondary mutations in exon 13) received $^{68}$Ga-Ga-NeoB (202 MBq) PET/CT for staging. A previously unknown isolated hypodense liver lesion in segment VII ($S_{\text{UV}_{\text{max}}} \text{ early of 11.2, } S_{\text{UV}_{\text{max}}} \text{ late of 16.6}$) was found (Fig. 3). Additionally, an abdominal wall metastasis in the left lower abdomen was found, which was not previously known from a three-month preliminary $^{18}$F-FDG PET/CT and was later proven histologically by surgical resection. In addition, physiological distribution of $^{68}$Ga-Ga-NeoB was visible in the study area. The single metastasis in liver segment VII was treated by IRE and no lesions were found by magnetic resonance imaging (MRI) follow-up 11 months later. Therefore, the patient was considered to have experienced a complete response.

Patient #3 (female, 51 years old, multiple progressive hepatic metastases of GIST of the stomach carrying a D842V mutation in PDGFRa and being pretreated as treated by SIRT and microwave ablation at previously known hepatic metastases. Three months later the patient received $^{68}$Ga-Ga-NeoB (135 MBq) PET/CT for staging (Fig. 4). An inhomogeneous, flat tracer accumulation within the uterine cavity with decrease of uptake in the temporal course ($S_{\text{UV}_{\text{max}}} \text{ 60 min p.i. of 26.5, } S_{\text{UV}_{\text{max}}} \text{ 120 min p.i. of 7.1, } S_{\text{UV}_{\text{max}}} \text{ 180 min p.i. of 6}$) was found, most likely a physiological enrichment. In addition, physiological radiopharmaceutical distribution in the study area was observed. However, there was no pathologically increased uptake of $^{68}$Ga-Ga-NeoB in the known hepatic metastatic lesions which had an unchanged morphology in comparison to the three-month previously performed $^{18}$F-FDG PET/CT. No tumor uptake and no new metastases were found in the region of interest also at later time-points indicating a stable disease. In the 120 min p.i. images, an increased nuclide uptake was found in the region of the gall bladder neck (Fig. 4b). However, after fatty eating, there was no correlation in 180 min p.i. images (Fig. 4c). An additional MRI follow-up examination six months after therapy was performed, which confirmed a stable disease.
Discussion

[68Ga]Ga-NeoB was produced routinely under GMP compliant conditions and was introduced in the clinical routine in three patients with different diagnostic scenarios. In the [68Ga]Ga-NeoB studies two new lesions in patient 1 and one more lesion in patient 2 were detected, which were not known previously. These results suggest that [68Ga]Ga-NeoB imaging may be an additional useful tool for detection of new lesions or metastases compared to conventional [18F]FDG PET/CT or MRI with unclear outcome. The uptake of the radiotracer in the newly detected metastases is mainly related to the overexpression of GRPR, which was histologically documented in our cases. However, patient #3 was stable between therapy and [68Ga]Ga-NeoB PET/CT follow-up and the patient had a complete response.

Additionally, patient #1 was assessed with a progressive disease because of increased high uptake in segment II/III and newly detected lesions, whereas the lesion in segment VII was confirmed stable showing no [68Ga]Ga-NeoB uptake after SIRT therapy. The reason for the higher uptake in segment II/III could be a possible increased GRPR expression in growing GIST lesions or in metabolic active phases [29]. Although patient #1 underwent SIRT and IRE, he showed a progressive disease in the follow-up examination after four months. It could be suggested, that endoradiotherapy with [177Lu]Lu/[225Ac]Ac-NeoB would be an additional, more specific therapeutic option to SIRT, IRE or MWA in patients with high GRPR-expressing lesions in multiple organs. However, it should be taken into account that if tumorous lesions known from morphologic imaging do not show a [68Ga]Ga-NeoB uptake, this might also be related to low GRPR expression [29].

It is well known that GIST have a wide spectrum of mutations, some of it with very low incidence [33]. Although 70–75% of GIST harbour imatinib-sensitive mutations of KIT [34], secondary resistances are often acquired within 2 years [22, 29, 35, 36]. The mechanisms of primary and secondary therapy resistance in GIST are not completely understood. It could be speculated that patients showing no uptake in [68Ga]Ga-NeoB PET/CT in lesions known from conventional [18F]FDG PET/CT or MRI imaging might have progressive disease and therapy resistance due to mutations affecting GRPRs. [68Ga]Ga-NeoB imaging could be a useful additional modality regarding monitoring of the effectiveness of a therapy of GIST patients and assisting to choose the type of therapy.

Conclusion

[68Ga]Ga-NeoB was successfully integrated in the clinical diagnostic procedures by routine production under GMP conditions. The application of the tracer could be introduced to the care of patients with GIST metastases in the liver and abdominal cavity. With the combination of PET/CT it was possible to evaluate therapy response in GIST patients with liver metastases. Patients who underwent [18F]FDG PET/CT with an inconclusive result on therapeutic response could benefit of an additional diagnostic approach with [68Ga]Ga-NeoB for characterization of GRPR-expressing tumors. In future, 177Lu/225Ac-
labeled NeoB may also be used for endoradiotherapy of high GRPR-expressing tumors. However, further clinical diagnostic studies are warranted prior to a therapeutic approach.

**Declarations**

**ETHICS APPROVAL**

The application of $^{68}$Ga-Ga-NeoB in patients with GIST was approved by the ethical vote 2014-912W-MA from 13.01.2015.

**CONSENT FOR PUBLICATION**

All data is consent for publication.

**AVAILABILITY OF DATA AND MATERIAL**

The data used and analysed during the current study are available from the corresponding author on reasonable request.

**COMPETING INTERESTS**

The authors declare that they have no competing interests

**FUNDING**

*This work was performed within the MITIGATE project, co-founded by the European Community's 7th Framework Programme (FP7/2007-2013, grant agreement no. 602306).*

**AUTHORS’ CONTRIBUTIONS**

MP, LR and BW were responsible for the radiopharmaceutical translation to clinical routine production and GMP conditions. MP, CW and PH analyzed and interpreted the patient data. MP, CW and PH were major contributor in writing the manuscript. SD, SOS and BW were responsible for funding of the project. SD, SOS and PH were responsible for selection of patients and study design. All authors read and approved the final manuscript. Study concept and design:

**ACKNOWLEDGEMENTS**

*The authors would like to thank AAA (a Novartis Company) for providing the NeoB-Kit. The authors thank Enrico Michler, Karen Büsing, Murat Sadic, and Ramon de Juan Rubio for fruitful discussions and evaluation of the PET images and Jörm Schmaljohann for excellent facilitation of GMP conform radiotracer production.*

**References**
1. El-Menyar A, Mekkodathil A, Al-Thani H. Diagnosis and management of gastrointestinal stromal tumors: An up-to-date literature review. J Cancer Res Ther. 2017;13(6):889–900.

2. Schaefer I-M, Mariño-Enríquez A, Fletcher JA. What is new in gastrointestinal stromal tumor? Adv Anat Pathol. 2017;24(5):259–67. doi:10.1097/pap.0000000000000158.

3. Joensuu H, Wardelmann E, Sihto H, Eriksson M, Sundby Hall K, Reichardt A, Hartmann JT, Pink D, Cameron S, Hohenberger P, Al-Batran SE, Schlemmer M, Bauer S, Nilsson B, Kallio R, Junnila J, Vehtari A, Reichardt P. Effect of KIT and PDGFRA mutations on survival in patients with gastrointestinal stromal tumors treated with adjuvant imatinib: An exploratory analysis of a randomized clinical trial. JAMA Oncol. 2017;3(5):602–9. doi:10.1001/jamaoncol.2016.5751. PubMed PMID: 28334365; PubMed Central PMCID: PMCPMC5470395. Epub 2017/03/24.

4. Antoch G, Herrmann K, Heusner TA, Buck AK. Bildgebende Verfahren bei gastrointestinalen Stromatumoren. Radiologe. 2009;49(12):1109–16. doi:10.1007/s00117-009-1852-9.

5. Pooja D, Gunukula A, Gupta N, Adams DJ, Kulhari H. Bombesin receptors as potential targets for anticancer drug delivery and imaging. Int J Biochem Cell Biol. 2019;114:105567. doi:10.1016/j.biocel.2019.105567. PubMed PMID: 31295552. Epub 2019/07/12.

6. Liolios C, Buchmüller B, Bauder-Wüst U, Schäfer M, Leotta K, Haberkorn U, Eder M, Kopka K. Monomeric and dimeric $^{68}$Ga-labeled bombesin analogues for positron emission tomography (PET) imaging of tumors expressing gastrin-releasing peptide receptors (GRPrs). J Med Chem. 2018;61(5):2062–74. doi:10.1021/acs.jmedchem.7b01856.

7. Baratto L, Duan H, Maecke HR, lagaru A. Imaging the Distribution of Gastrin Releasing Peptide Receptors in Cancer. J Nucl Med. 2020:1–29. doi: 10.2967/jnumed.119.234971.

8. Markwalder R, Reubi JC. Gastrin-releasing peptide receptors in the human prostate: Relation to neoplastic transformation. Cancer Res. 1999;59:1152–9.

9. Halmos G, Wittliff JL, Schally AV. Characterization of bombesin/gastrin-releasing peptide receptors in human breast cancer and their relationship to steroid receptor expression. Cancer Res. 1995;55:280–7.

10. Reubi JC, Körner M, Waser B, Mazzucchelli L, Guillou L. High expression of peptide receptors as a novel target in gastrointestinal stromal tumours. Eur J Nucl Med Mol Imaging. 2004;31(6):803–10. doi:10.1007/s00259-004-1476-2. PubMed PMID: 14985869.

11. Reubi JC, Wenger S, Schmuckli-Maurer J, Schauer J-C, Gugger M. Bombesin receptor subtypes in human cancers: Detection with the universal radioligand $^{125}$I-[D-Tyr$^6$, b-ALA$^{11}$, PHE$^{13}$, NLE$^{14}$]bombesin(6–14). Clin Cancer Res. 2002;8:1139–46.

12. Cornelio DB, Roesler R, Schwartzmann G. Gastrin-releasing peptide receptor as a molecular target in experimental anticancer therapy. Ann Oncol. 2007;18(9):1457–66. doi:10.1093/annonc/mdm058. PubMed PMID: 17351255.

13. Reubi JC. Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr Rev. 2003;24(4):389–427. doi: 10.1210/er.2002-0007. PubMed PMID: 12920149.
14. Smith CJ, Volkert WA, Hoffman TJ. Gastrin releasing peptide (GRP) receptor targeted radiopharmaceuticals: A concise update. Nucl Med Biol. 2003;30(8):861–8. doi:10.1016/s0969-8051(03)00116-1.

15. Gonzalez N, Moody TW, Igarashi H, Ito T, Jensen RT. Bombesin-related peptides and their receptors: recent advances in their role in physiology and disease states. Curr Opin Endocrinol Diabetes Obes. 2008;15(1):58–64. doi:10.1097/MED.0b013e3282f3709b. PubMed PMID: 18185064; PubMed Central PMCID: PMC2631407.

16. Dimitrakopoulou-Strauss A, Hohenberger P, Haberkorn U, Mäcke HR, Eisenhut M, Strauss LG. $^{68}$Ga-labeled bombesin studies in patients with gastrointestinatal stromal tumors: Comparison with $^{18}$F-FDG. J Nucl Med. 2007;48(8):1245–50. doi:10.2967/jnumed.106.038091. PubMed PMID: 17631559.

17. Richter S, Wuest M, Krieger SS, Rogers BE, Friebe M, Bergmann R, Wuest F. Synthesis and radiopharmacological evaluation of a high-affinity and metabolically stabilized $^{18}$F-labeled bombesin analogue for molecular imaging of gastrin-releasing peptide receptor-expressing prostate cancer. Nucl Med Biol. 2013;40(8):1025–34. doi: 10.1016/j.nucmedbio.2013.07.005. PubMed PMID: 23969085.

18. Rogers BE, Bigott HM, McCarthy DW, Manna DD, Kim J, Sharp TL, Welch MJ. MicroPET imaging of a Gastrin-releasing peptide receptor-positive tumor in a mouse model of human prostate cancer using a $^{64}$Cu-labeled bombesin analogue. Bioconjugate Chem. 2003;14:756–63.

19. Schuhmacher J, Zhang H, Doll J, Mäcke HR, Matys R, Hauser H, Henze M, Haberkorn U, Eisenhut M. GRP receptor-targeted PET of a rat pancreas carcinoma xenograft in nude mice with a $^{68}$Ga-labeled bombesin(6–14) analog. J Nucl Med. 2005;46.

20. Baidoo KE, Lin K-S, Zhan Y, Finley P, Scheffel U, Wagner Jr. HN. Design, synthesis, and initial evaluation of high-affinity technetium bombesin analogues. Bioconjugate Chem. 1998;9:218–25.

21. Zhang H, Chen J, Waldherr C, Hinni K, Waser B, Reubi JC, Mæcke HR. Synthesis and evaluation of bombesin derivatives on the basis of pan-bombesin peptides labeled with indium-111, lutetium-177, and yttrium-90 for targeting Bombesin receptor-expressing tumors. Cancer Res. 2004;64:6707–15.

22. Breeman WAP, de Jong M, Bernard BF, Kwekkeboom DJ, Srinivasan A, van der Pluijm ME, Hofland LJ, Visser TJ, Krenning EP. Pre-clinical evaluation of $[^{111}$In-DTPA-Pro$^1$,Tyr$^4$]bombesin, a new radioligand for bombesin-receptor scintigraphy. Int J Cancer. 1999;83:657–63.

23. Chatalic KL, Konijnenberg M, Nonnekens J, de Blois E, Hoeben S, de Ridder C, Brunel L, Fehrentz JA, Martinez J, van Gent DC, Nock BA, Maina T, van Weerden WM, de Jong M. In vivo stabilization of a Gastrin-releasing peptide receptor antagonist enhances PET imaging and radionuclide therapy of prostate cancer in preclinical studies. Theranostics. 2016;6(1):104–17. doi:10.7150/thno.13580. PubMed PMID: 26722377; PubMed Central PMCID: PMCPMC4679358. Epub 2016/01/02.

24. Chatalic KLS, Konijnenberg M, Nonnekens J, de Blois E, Hoeben S, de Ridder C, Brunel L, Fehrentz JA, Martinez J, van Gent DC, Nock BA, Maina T, van Weerden WM, de Jong M. In Vivo Stabilization of a Gastrin-Releasing Peptide Receptor Antagonist Enhances PET Imaging and Radionuclide Therapy of Prostate Cancer in Preclinical Studies. Theranostics. 2016;6(1):104–17. doi:10.7150/thno.13580.
25. Valverde IE, Huxol E, Mindt TL. Radiolabeled antagonistic bombesin peptidomimetics for tumor targeting. J Labelled Compd Radiopharm. 2014;57(4):275–8. doi:10.1002/jlcr.3162. PubMed PMID: 24327435.

26. Lindner S, Michler C, Wängler B, Bartenstein P, Fischer G, Schirrmacher R, Wängler C. PESIN multimerization improves receptor avidities and in vivo tumor targeting properties to GRPR-overexpressing tumors. Bioconjugate Chem. 2014;25(3):489–500. doi:10.1021/bc4004662. PubMed PMID: 24533789. Epub 2014/02/19.

27. Pretze M, Hien A, Radle M, Schirrmacher R, Wängler C, Wängler B. Gastrin-releasing peptide receptor- and prostate-specific membrane antigen-specific ultrasmall gold nanoparticles for characterization and diagnosis of prostate carcinoma via fluorescence imaging. Bioconjugate Chem. 2018;29(5):1525–33. doi:10.1021/acs.bioconjchem.8b00067. PubMed PMID: 29542916. Epub 2018/03/16.

28. Nock BA, Kaloudi A, Lymperis E, Giarika A, Kulkarni HR, Klette I, Singh A, Krenning EP, de Jong M, Maina T, Baum RP. Theranostic perspectives in prostate cancer with the gastrin-releasing peptide receptor antagonist NeoBOMB1: Preclinical and first clinical results. J Nucl Med. 2017;58(1):75–80. doi:10.2967/jnumed.116.178889. PubMed PMID: 27493272.

29. Gruber L, Jimenez-Franco LD, Decristoforo C, Uprimny C, Glatting G, Hohenberger P, Schoenberg SO, Reindl W, Orlandi F, Mariani M, Jaschke W, Virgolini IJ. MITIGATE-NeoBOMB1, a Phase I/IIa Study to Evaluate Safety, Pharmacokinetics and Preliminary Imaging of (68)Ga-NeoBOMB1, a Gastrin-releasing Peptide Receptor Antagonist, in GIST Patients. J Nucl Med. 2020. doi:10.2967/jnumed.119.238808. PubMed PMID: 32332143. Epub 2020/04/26.

30. Todde S, Peitl PK, Elsinga P, Koziorkowski J, Ferrari V, Ocak EM, Hjelstuen O, Patt M, Mindt TL, Behe M. Guidance on validation and qualification of processes and operations involving radiopharmaceuticals. EJNMMI Radiopharm Chem. 2017;2(1):8. doi:10.1186/s41181-017-0025-9. PubMed PMID: 29503849; PubMed Central PMCID: PMC5824699. Epub 2017/01/01.

31. GALLIUM ([68]Ga) EDOTREOTIDE INJECTION. PHARMEUROPA. 2011;23(2).

32. Eder M, Neels O, Müller M, Bauder-Wüst U, Remde Y, Schäfer M, Henrich U, Eisenhut M, Afshar-Oromieh A, Haberkorn U, Kopka K. Novel Preclinical and Radiopharmaceutical Aspects of [68]Ga-PSMA-HBED-CC: A New PET Tracer for Imaging of Prostate Cancer. Pharmaceuticals. 2014;7(7):779–96. doi:10.3390/ph7070779. PubMed PMID: 24983957; PubMed Central PMCID: PMC4113732.

33. Lasota J, Stachura J, Miettinen M. GISTs with PDGFRA exon 14 mutations represent subset of clinically favorable gastric tumors with epithelioid morphology. Lab Invest. 2006;86(1):94–100. doi:10.1038/labinvest.3700360. PubMed PMID: 16258521. Epub 2005/11/01.

34. Linch M, Claus J, Benson C. Update on imatinib for gastrointestinal stromal tumors: duration of treatment. Onco Targets Ther. 2013;6:1011–23. doi:10.2147/OTT.S31260.

35. Takahashi T, Elzawahry A, Mimaki S, Furukawa E, Nakatsuka R, Nakamura H, Nishigaki T, Serada S, Naka T, Hirota S, Shibata T, Tsuchihara K, Nishida T, Kato M. Genomic and transcriptomic analysis of
imatinib resistance in gastrointestinal stromal tumors. Genes Chromosomes Cancer. 2017;56(4):303–13. doi:10.1002/gcc.22438. PubMed PMID: 27997714; PubMed Central PMCID: PMCPMC5324566. Epub 2016/12/21.

36. Wardelmann E, Thomas N, Merkelbach-Bruse S, Pauls K, Speidel N, Büttner R, Bihl H, Leutner CC, Heinicke T, Hohenberger P. Acquired resistance to imatinib in gastrointestinal stromal tumours caused by multiple KIT mutations. Lancet Oncol. 2005;6:249–51. doi:10.1016/S1470-2045(05)70097-8.

Figures

Figure 1

a) Maximum-intensity-projections (MIP) of (i, 57) 1 h p.i. b) 2 h p.i. left, front, right, behind.
Figure 2

MIP of (i, 77) 1 h p.i. b) 2 h p.i. left, front, right, behind.
Figure 3

a) MIP of (i, 57) 1 h p.i. b) 2 h p.i., and c) 3 h p.i. left, front, right, behind.